logo
logooffcanvas
logooffcanvas

Adult Patients

XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol
has been shown to deliver fast and consistent asthma relief and is well tolerated in adults.1-3

*On Day 1, the median duration of effect was 3 to 4 hours, with a duration of effect in some patients of up to 6 hours.

Data from 2 double-blind, randomized, placebo- and active-controlled, multicenter, parallel-group, 8-week trials of patients aged ≥12 years (N=748) with moderate-to-severe asthma (FEV1 was ≥45% to ≤75% predicted). Primary endpoint was peak percent change from visit predose in FEV1 averaged over the double-blind period.

  • There was a significantly larger peak percent change in FEV1 from visit predose with XOPENEX HFA® (levalbuterol tartrate) relative to the placebo group averaged over the double-blind period (primary endpoint) (P<0.001)2,3

Low incidence of β-mediated adverse events2,3

Adverse event information concerning XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol in adults and adolescents is derived from two 8-week, multicenter, randomized, double-blind, active- and placebo-controlled trials in 748 adult and adolescent patients with asthma that compared XOPENEX HFA Inhalation Aerosol, a marketed albuterol HFA inhaler, and an HFA-134a placebo inhaler.

  • The most common adverse events in patients aged 12 years and older (occurring in ≥2% of patients receiving XOPENEX HFA at 90 mcg and more frequently than patients receiving placebo) were asthma, pharyngitis, rhinitis, pain, and dizziness1
  • XOPENEX brand of levalbuterol and other β-agonists can cause paradoxical bronchospasm, which may be life threatening

 

References:
1. XOPENEX HFA Inhalation Aerosol [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; June 2009.
2. Data on file, NCT00073840. CSR 051-355. Sunovion Pharmaceuticals Inc.
3. Data on file, NCT00073827. CSR 051-353. Sunovion Pharmaceuticals Inc.

Connect With Sunovion
 Call (888) 394-7377
or
 Submit A Medical Inquiry

Important Safety Information & Indication

XOPENEX HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol tartrate, racemic albuterol, or any component of the drug product. 

Patients receiving the highest dose of XOPENEX HFA should be monitored closely for adverse effects, and the risk of such effects should be balanced against the potential for improved efficacy.

XOPENEX HFA and other β-agonists can cause paradoxical bronchospasm, which may be life threatening.

XOPENEX HFA like other β-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients as measured by heart rate, blood pressure, and/or symptoms.

Potential drug interactions include: β-blockers, which can block the pulmonary effect of β-agonists and can cause severe bronchospasm in asthmatic patients; diuretics (non-potassium-sparing), whose ECG changes and/or hypokalemia side effects can worsen with administration of β-agonists; digoxin, where serum levels can decrease 16% to 22% with administration of β-agonists; monoamine oxidase inhibitors and tricyclic antidepressants, which can potentiate the action of albuterol on the vascular system. 

If additional adrenergic drugs, including other short-acting sympathomimetic bronchodilators or epinephrine, are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Due to the cardiovascular side effects associated with β-agonists, caution is generally recommended for patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), diabetes, hyperthyroidism, or convulsive disorders.

In patients aged 4 to 11 years, the most common adverse events (occurring in ≥2% of patients receiving XOPENEX HFA at 90 mcg and more frequently than patients receiving placebo) were vomiting, accidental injury, pharyngitis, and bronchitis.

In patients 12 years and older, the most common adverse events (occurring in ≥2% of patients receiving XOPENEX HFA at 90 mcg and more frequently than patients receiving placebo) were asthma, pharyngitis, rhinitis, pain, and dizziness.

For more information about XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, please see the full Prescribing Information including Patient's Instructions for Use or visit www.xopenex.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication
XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc.

APTIOM is a registered trademark of , used under license.  LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

ARCAPTA, , and NEOHALER are registered trademarks of Novartis AG, used under license.  SEEBRI, , UTIBRON, and, , are trademarks of Novartis AG, used under license.

LONHALA and are trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a trademark of PARI Pharma GmbH, used under license.

eFlow and eLete are registered trademarks of PARI Pharma GmbH.

This site contains information intended for U.S. health care professionals only.

© 2018 Sunovion Pharmaceuticals Inc. All rights reserved. 04/16 XOP002-16